Substantial doubt about the company's ability to continue as a going concern.
“management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
4 customers — 96% of revenue (the three months ended June 30, 2026)
“The Company had four customers during the three and six months ended June 30, 2026, each of which individually generated 10% or more of the Company’s total revenue. These customers accounted for 96% and 95% of the Company’s revenue for the three and six months ended June 30, 2026, respectively, individually ranging from 22% to 27% and 19% to 27%.”
4 customers — 95% of revenue (the six months ended June 30, 2026)
“The Company had four customers during the three and six months ended June 30, 2026, each of which individually generated 10% or more of the Company’s total revenue. These customers accounted for 96% and 95% of the Company’s revenue for the three and six months ended June 30, 2026, respectively, individually ranging from 22% to 27% and 19% to 27%.”
4 customers — 80% of receivables (As of June 30, 2026)
“As of each of June 30, 2026 and 2025, these customers represented 80% and 99% of the Company’s outstanding accounts receivable, individually ranging between 16% and 37%, and 19% and 30% for respective periods.”
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Scilex Holding Company increased its uncommitted revolving line of credit to Vivasor from $20,000,000 to $30,000,000 on September 25, 2026; no other changes were made to the Promissory Note.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SCLX
this stock
Scilex Holding Co
|
$14.44M | — | -46.5% | — | 2.1% |
|
LLY
ELI LILLY & Co
|
$1.28T | +26.0% | +44.7% | 44.3 | 0.7% |
|
JNJ
Johnson & Johnson
|
$655.56B | +33.5% | +6.0% | 41.4 | 0.7% |
|
ABBV
AbbVie Inc.
|
$514.92B | +27.5% | +8.6% | 50.1 | 0.9% |
|
MRK
Merck & Co., Inc.
|
$362.24B | +39.4% | +1.3% | 151.5 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Scilex Holding Company increased its uncommitted revolving line of credit to Vivasor from $20,000,000 to $30,000,000 on September 25, 2026; no other changes were made to the Promissory Note.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SCLX | -8.1% | -41.8% | -54.3% | -8.1% | -77.6% |
| SPY | -2.7% | -5.6% | -0.5% | -2.7% | +7.8% |
| vs SPY | -5.4% | -36.2% | -53.9% | -5.4% | -85.5% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
